
Chinese Medical Journal, Journal Year: 2025, Volume and Issue: unknown
Published: March 14, 2025
Transcranial alternating current stimulation (tACS) is a noninvasive neuromodulation technique that regulates brain function by applying sinusoidal currents of specific frequencies to targeted regions through the scalp electrodes.[1] This guideline aims evaluate and summarize efficacy safety tACS in clinical applications. We conducted structured literature search across major databases using terms "tACS" or "transcranial stimulation" identify all relevant up June 2022. After rigorous screening, total 35 articles were included this (the detailed screening process illustrated Supplementary Figure 1, https://links.lww.com/CM9/C402). The uses Grades Recommendation, Assessment, Development, Evaluation (GRADE) evidence quality evaluation recommendation strength grading standards established World Health Organization (WHO) for these trials.[2] Following Delphi method, electronic questionnaires distributed multiple specialized groups. collection, summarization, feedback, application opinions grades various diseases finalized (detailed procedures are provided Material procedures: commonly used methods can be categorized into three types based on intensity: superhigh-energy (superhigh tACS, intensity >100 mA), high-energy (high >10–100 medium-energy (medium 4–10 mA) low-energy (low <4 mA).[3] Within certain range, higher intensities result broader range endogenous effects, stronger entrainment capabilities, deeper penetration.[4] In article, same phase electrodes "[]", whereas different electrodes/groups separated "-". If loops exist, they ";". frequency another critical parameter. Low (θ waves, 4–7 Hz) often promote relaxation improve sleep, (γ 30–100 may enhance cognitive functions alertness. Detailed protocols operational described 2, https://links.lww.com/CM9/C402. Clinical applications tACS:Insomnia disorder: modulate cortical excitability function, sleep efficiency quality, alleviate insomnia symptoms influencing synchronization desynchronization neuronal electrical activity brain. High-quality indicates 15 mA, 77.5 Hz with placed at [prefrontal lobe]-[bilateral mastoid] improves chronic patients. Low-quality suggests 0.75 [F3]-[left mastoid area]; [F4]-[right area] also patients information Table Recommendations: For patients, high region]-[bilateral strongly recommended quality. might useful improving Cognitive dysfunction Alzheimer's disease (AD): studies have primarily focused mild impairment (MCI) mild-to-moderate dementia. Some who diagnosed definitively AD pathologic examination. 2 40 over bilateral temporal enhances Moderate-quality 3 [Pz]-[right deltoid] episodic memory MCI low-quality did not find therapeutic effect detectable scales but reduce p-Tau burden. combined training longer duration than alone. sound weeks Fourteen home-based treatment AD-related dementia addition, appears offer superior benefits compared transcranial direct (tDCS) low region function. recommended. Chronic pain: 10 [F3, F4]-[Pz] alleviates back pain. 1–2 mA 4 30 (depending individual's dominant spectral power) [the highest power spectrum difference area]-[ipsilateral could pain fibromyalgia syndrome Low-level acute 0.4 140 [Oz]-[Cz] min effectively terminate migraine attacks 3, weakly symptoms. [Oz] – [Cz] Vestibular individual alpha [prefrontal]-[occipital] (2 [prefrontal, occipital]-[left upper arm] (4 20 per session 10–12 sessions oscillatory vertigo Mal de Débarquement Syndrome (MdDS) former configuration more effective, stimulating slightly preferable 4, MdDS vertigo. Stimulating preferable. Stroke rehabilitation: weeks, rehabilitation training, overall functional recovery subacute supratentorial intracerebral hemorrhage infarction 5, subacute-stage stroke recovery. Parkinson's disease: combining motor functions. Furthermore, [forehead]-[bilateral 45 has no significant effects mood 6, Epilepsy: most frequent interictal epileptiform discharge supraorbital region] 60 5 days fails seizure multifocal refractory epilepsy (including lobe epilepsy, frontal Lennox–Gastaut syndrome). Very 1 [Fp1]-[Fp2] daily increased 75% 16-year-old female myoclonic followed 15-day seizure-free period 7, No recommendations due insufficient evidence. Depressive disorders depressive states): from significantly shows F4]-[Cz] yields better antidepressant outcomes tACS. [F3]-[F4] twice reduces 8, depression, Combining antidepressants advised outcomes. Schizophrenia psychotic symptoms): between F3 Fp1, T3 P3]-[Cz] auditory hallucinations. Another moderate 6 [F1, F5, AF3, FC3]-[CPz]; [P1, P5, CP3, PO3]-[FCz] negative schizophrenia [AFz]-[Cz] severity delusions, [F3]-[P3] working 9, Substance addiction: habitual behaviors individuals substance addiction 10, https://links.lww.com/CM9/C402) Tolerability therapy: tolerability favorable. Common adverse reactions including photophobia (flash, phosphenes), itching, burning, tingling, fever, dizziness, headache, burning being frequently reported. 11, https://links.lww.com/CM9/C402 common observed during therapy provide management strategies. 12, outlines populations. continuous monitoring participants' responses administration advised, meticulous inspection electrode-skin interface should performed before after each session. Prospects tACS: With advancements neuroscience, future research expected establish disease-specific frequency-intensity-target models multimodal technologies develop personalized strategies neural oscillations genetic characteristics. widespread will ultimately depend evidence-based validation establishment standardized technical guidelines. Members Expert Steering Group( sorted last name) Dongmei An, Xuebing Cao, Haobo Chen, Ling Guiyun Cui, Jiahui Deng, Wei Jing Ding, Tao Feng, Zhengzhi Yuan Geng, Qiang Guan, Yi Guo, Yue Hou, Shaohua Hu, Yonghua Huang, Li Kuang, Tongliang Li, Zhe Zhanhua Liang, Jun Liu, Xuedong Yiming Xiaoyan Long, Jinghong Ma, Yan Mei, Xianghong Meng, Yijun Song, Chaoxia Su, Shujuan Tian, Yuling Zhirong Wan, Chunxue Wang, Jijun Kai Lin Mengyang Mingwei Qing Qun Xiaorong Yanyong Yuping Zan Shenhong Weng, Bingjie Wu, Jianjun Wenqing Yuncheng Anmu Xie, Fengquan Xu, Yuehong Zhi Liqing Yan, Xinling Yang, Qinyong Ye, Jie Yuan, Yonggui Lingyun Zeng, Linwei Zhang, Xiong Yang Yuhu Peng Zheng, Di Zhong, Bo Zhou, Hongcan Zhu. Acknowledgments authors acknowledge assistance Nan Hua Minyue Pei, Epidemiology Research Center, Peking University Third Hospital. Funding study was supported grants National Key Development Program China (Nos. 2021YFC2501400, 2021YFC2501404). Conflicts interest None.
Language: Английский